Business Context and Reporting Period
Unicycive Therapeutics, Inc. (UNCY), an emerging growth company incorporated in Delaware, filed this Form 8-K on June 5, 2026. The report details a material definitive agreement regarding the company's capital raising activities.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the expansion of the company's "at-the-market" (ATM) equity offering capacity.
- Previous ATM Offering Limit: $100,000,000
- New ATM Offering Limit: $150,000,000
- Incremental Capacity Added: $50,000,000
- Sales Agent: Guggenheim Securities, LLC
Material Changes
On June 5, 2026, the Company entered into Amendment No. 2 to its Sales Agreement with Guggenheim Securities, LLC. This amendment increased the aggregate offering price of common stock available for sale under the ATM Offering from $100 million to $150 million. Concurrently, the Company filed a Shelf Registration Statement on Form S-3 to register the additional $50 million in shares.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks beyond standard securities law disclaimers. The document explicitly states it does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current share price and trading volume of UNCY on the Nasdaq Capital Market to assess the potential dilution impact of the new $50 million offering capacity.
- Review the full text of Amendment No. 2 (Exhibit 1.1) for specific terms regarding the sales agent's commission and any restrictions on share sales.
- Check the Company's most recent 10-Q or 10-K filing for current cash reserves and burn rate to understand the urgency of this capital raise.
- Confirm the status of the Form S-3 registration statement to ensure the new shares are eligible for immediate sale.